Internal Medicine

Cutaneous lupus

Questions discussed in this category

How do you utilize anifrolumab for SLE in your practice?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Long-term outcomes of anifrolumab in SLE.

2 Answers available

Papers discussed in this category

Autoimmunity reviews, 2009-02

The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus.

Journal of the American Academy of Dermatology, 2011-05

Quality of life in cutaneous lupus erythematosus.

Arthritis and rheumatism, 2013-07

Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio.

Arthritis Rheumatol, 2021 Mar 24

Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.

Rev Med Interne, 2016 Oct 13

[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].

Arthritis Care Res (Hoboken), 2021 Mar 30

Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

JAMA Dermatol,

Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.

Mod Rheumatol, 2020 Sep 17

Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.

Ann Rheum Dis, 2014 Feb 13

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.

Ann Rheum Dis, 2019 Jan 04

Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.

Ann Rheum Dis, 2014 Apr 16

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

Arthritis & rheumatology (Hoboken, N.J.), 2023 Jun 01

Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus Erythematosus.

Annals of the rheumatic diseases, 2023 Oct 12

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

Lupus science & medicine, 2024 May 22

Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations.

The Lancet. Rheumatology, 2019 Nov 25

Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study.

N Engl J Med, 2019 Dec 18

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

Related Topics in Internal Medicine